Impact of the use of ultrasound contrast agent on the detection of thrombi in the left atrial appendage during transesophageal echocardiography (CONDOR)

Not Applicable

• Conditions: I48; Atrial fibrillation and flutter

• Registration Number: DRKS00011716
• Lead Sponsor: Katholisches Krankenhaus St. Johan Nepomuk Erfurt

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-02-23
• Study Completion: 2018-10-01
• Results First Posted: 2019-09-26
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 223

Inclusion Criteria

age > 18 years; documented atrial fibrillation (paroxysmal or persistent or permanent); clinical indication for TOE because of scheduled cardioversion or LAA closure; signed informed consent

Exclusion Criteria

history of LAA closure (either interventional or surgical); allergy against SonoVue; intracardiac shunt, severe pulmonary hypertension, uncontrolled arterial hypertension, acute respiratory distress syndrome

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
frequency of detected thrombi in the LAA by transesophageal echocardiography in dependance of the use of echo contrast agent (with contrast agent /wo contrast agent)

Secondary Outcome Measures

Name	Time	Method
size of the LAA ostium (minimal/ mean/ maximal diameter) with and without contrast agent